149794-10-5

Basic information

• Product Name: BOC-N-ETHYL GLYCINE
• Synonyms: N-BOC-N-ETHYL-GLYCINE;BOC-N-ETHYL GLYCINE;BOC-N-ETHYLGLY-OH;N-(tert-Butoxycarbonyl)-N-ethylglycine;2-(tert-butoxycarbonyl(ethyl)amino)acetic acid;Boc-N-ethyl glycine≥ 98% (HPLC)
• CAS NO: 149794-10-5
• Molecular Formula: C₉H₁₇NO₄
• Molecular Weight: 203.24
• Product Categories: Amino Acid Derivatives;Amino Acids
• Mol File: 149794-10-5.mol
• Article Data: 18

Chemical Properties

• Melting Point: 87-88℃
• Boiling Point: 302.729 °C at 760 mmHg
• Flash Point: 136.886 °C
• Appearance: /
• Density: 1.114 g/cm³
• Storage Temp.: Store at 0°C
• PKA: 4.03±0.10(Predicted)
• CAS DataBase Reference: BOC-N-ETHYL GLYCINE(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-N-ETHYL GLYCINE(149794-10-5)
• EPA Substance Registry System: BOC-N-ETHYL GLYCINE(149794-10-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 149794-10-5(Hazardous Substances Data)

Usage

Description

BOC-N-ETHYL GLYCINE, also known as N-Boc-N-ethyl Glycine, is a substituted Glycine derivative (G615990) characterized by its white powder form. It is a crucial building block for the synthesis of more complex pharmaceutical compounds, particularly in the development of peptide-based fibrinogen receptor antagonists. Its chemical structure allows for the creation of potent, selective, and orally active medications.

Uses

Used in Pharmaceutical Industry:
BOC-N-ETHYL GLYCINE is used as a building block for the synthesis of complex pharmaceutical compounds. Its application is primarily due to its ability to contribute to the development of potent, selective, and orally active peptide-based fibrinogen receptor antagonists, which have potential therapeutic applications in various medical conditions.
Used in Drug Design:
BOC-N-ETHYL GLYCINE is used as a key component in drug design, specifically for creating peptide-based fibrinogen receptor antagonists. The reason for its use in this application is its ability to enhance the potency, selectivity, and oral activity of the resulting pharmaceutical compounds, making them more effective and accessible for patients.

Upstream product

• 4530-20-5 BOC-glycine 
• 75-03-6 ethyl iodide 
• 627-01-0 N-ethylglycine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 623-33-6 glycine ethyl ester hydrochloride 
• 1249016-05-4 methyl N-(tert-butoxycarbonyl)-N-ethylglycinate 
• 22889-78-7 3,5-dichloro-4-aminopyridine 
• 98-80-6 phenylboronic acid 
• 6456-74-2 Glycine tert-butyl ester 
• 84532-85-4 methyl 2-(ethylamino)acetate 

Downstream Products

• 659734-30-2 [(5-chloro-2-methylphenylcarbamoyl)methyl]ethylcarbamic acid tert-butyl ester 
• 659734-31-3 [(5-chloro-2-methylphenylthiocarbamoyl)methyl]ethylcarbamic acid tert-butyl ester 
• 204139-57-1 (S)-3-[2-(tert-Butoxycarbonyl-ethyl-amino)-acetylamino]-N-((S)-1-carbamoyl-2-cyclohexyl-ethyl)-succinamic acid benzyl ester 
• 194933-86-3 (S)-2-{(S)-3-Benzyloxycarbonyl-2-[2-(tert-butoxycarbonyl-ethyl-amino)-acetylamino]-propionylamino}-3-methyl-butyric acid benzyl ester 

Relevant articles and documents

A Naphthalimide-Based Cd2+Fluorescent Probe with Carbamoylmethyl Groups Working as Chelators and PET-Promoters under Neutral Conditions

We have developed a novel naphthalimide-based Cd2+fluorescent probe (1), featuring almost no background response, high sensitivity and selectivity toward Cd2+through its high association constant [K=(2.10±0.423)×106], and a practical working pH range. Membrane-permeability was conferred on 1 by replacing the imide and amide substituents with n-butyl groups, and hence the derivative (4) has found practical utility on fluorescent imaging of Cd2+in HeLa cells. Comparison of fluorescent properties between various compounds derived from 1 has demonstrated that the carbamoylmethyl groups in 1 function not only as Cd2+chelators but also as promoters for photoinduced electron transfer (PET) by lowering the basicity of the two tertiary amino groups. As a result, 1 and 4 exhibited highly practical performance as Cd2+probes under neutral conditions.

HETEROARYL COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES

Provided in the present disclosure are immunotherapy compounds, pharmaceutical compositions thereof and their use, wherein the immunotherapy compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.